首页> 外国专利> INCREASING EXPRESSION OF INTERFERON REGULATED GENES WITH COMBINATONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

INCREASING EXPRESSION OF INTERFERON REGULATED GENES WITH COMBINATONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS

机译:带有组氨酸去乙酰化抑制剂和免疫调节药物组合的干扰素调控基因的表达

摘要

Provided herein is a combination comprising an HDAC inhibitor and an IMiD for increasing interferon regulated gene expression or decreasing c-MYC gene expression in a cancer cell or tumor in a subject in need thereof. Increasing interferon regulated gene expression may result in increased recognition of tumors by innate or adaptive immune system and an increase in programmed cell death (apoptosis) gene expression, increasing apoptosis in cancer cells and tumors. The cells can be multiple myeloma cells or diffuse large B-cell lymphoma cells. Also provided are methods for treating myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) or pathogen infections in a subject in need thereof comprising administering to the subject an effective amount of HDAC inhibitor and an IMiD. The HDAC inhibitor can be an HDAC6-selective inhibitor.
机译:本文提供了包含HDAC抑制剂和IMiD的组合,用于在需要其的受试者的癌细胞或肿瘤中增加干扰素调节的基因表达或降低c-MYC基因的表达。干扰素调节的基因表达的增加可能导致先天性或适应性免疫系统对肿瘤的识别增加,程序性细胞死亡(凋亡)基因表达的增加,癌细胞和肿瘤的凋亡增加。这些细胞可以是多发性骨髓瘤细胞或弥漫性大B细胞淋巴瘤细胞。还提供了在有此需要的受试者中治疗骨髓增生异常综合症/急性髓细胞性白血病(MDS / AML)或病原体感染的方法,该方法包括向受试者施用有效量的HDAC抑制剂和IMiD。 HDAC抑制剂可以是HDAC6选择性抑制剂。

著录项

  • 公开/公告号WO2017143237A1

    专利类型

  • 公开/公告日2017-08-24

    原文格式PDF

  • 申请/专利权人 ACETYLON PHARMACEUTICALS INC.;

    申请/专利号WO2017US18445

  • 申请日2017-02-17

  • 分类号A61K31/505;A61K31/454;C07D239/42;C07D401/04;

  • 国家 WO

  • 入库时间 2022-08-21 13:30:01

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号